Reply to: S. N. Katkuri et al. and H. Liu et al. on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)
Open Access
- 17 April 2026
- journal article
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (5) , 534-536
Abstract
No abstract availableFunding Information
- AstraZeneca
This publication has 6 references indexed in Scilit:
- Correspondence Regarding “Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)”International Forum of Allergy & Rhinology, 2026
- Early Olfactory Recovery With Tezepelumab in CRSwNP: Mechanistic and Clinical ConsiderationsInternational Forum of Allergy & Rhinology, 2026
- Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)International Forum of Allergy & Rhinology, 2026
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal PolypsNew England Journal of Medicine, 2025
- Outcome measures for chronic rhinosinusitis with nasal polypsRhinology journal, 2024
- The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polypsFrontiers in Immunology, 2024